← All organizations
Highest phase reached
Phase 4
Timeline
1990s
- Jun 1, 1995
GW Research— Founded
2010s
- Jun 25, 2018
cannabidiol— NDA Secondary Org
Drugs by trial phase (6 distinct, 40 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Indications
Studied for
- Autism Spectrum Disorder
- Autistic Disorder
- Cerebral Palsy
- Child Development Disorders, Pervasive
- Colitis
- Colitis, Ulcerative
- Constipation
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Dyslipidemias
- Epilepsies, Myoclonic
- Epilepsy
- Fatty Liver
- Glioblastoma
- Heroin Dependence
- Lennox Gastaut Syndrome
- Liver Diseases
- Mental Disorders
- Multiple Sclerosis
- Muscle Spasticity
- Opioid-Related Disorders
- Parkinson Disease
- Psychotic Disorders
- Rett Syndrome
- Schizophrenia
- Sclerosis
- Seizures
- Spasm
- Spasms, Infantile
- Substance-Related Disorders
- Syndrome
- Tremor
- Tuberous Sclerosis
- Ulcer
- Weight Gain
Marketed drugs (1)
Recent trials (40)
- NCT05733390CollaboratorPhase 2Jun 30, 2023
- NCT05044819Lead sponsorPhase 4Jul 7, 2021
- NCT04745026Lead sponsorPhase 2May 31, 2021
- NCT04567784CollaboratorPhase 2Nov 12, 2020
- NCT04485104Lead sponsorPhase 3Sep 30, 2020
- NCT04421456Lead sponsorPhase 2Jun 30, 2020
- NCT04252586Lead sponsorPhase 3Feb 20, 2020
- NCT04133480Lead sponsorPhase 4Dec 9, 2019
- NCT03848832Lead sponsorPhase 3Jun 30, 2019
- NCT03849456Lead sponsorPhase 2May 31, 2019
- NCT02954887Lead sponsorPhase 3Apr 1, 2017
- NCT02953548Lead sponsorPhase 3Mar 16, 2017
- NCT03097861Overall official - principal investigatorPhase 3Feb 13, 2017
- NCT02607904Lead sponsorPhase 2Nov 1, 2016
- NCT02607891Lead sponsorPhase 2Oct 1, 2016
Details
- Founded
- London, GB Jun 1, 1995
- Last known activity
- Jun 30, 2023